Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 127 references it cites were found in a registry or an index; 18 of the 86 sources its claims cite were checked for support.

A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse

Open access

Abstract

The process of stopping antipsychotics may be causally related to relapse, potentially linked to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity. Therefore, the risk of relapse on cessation of antipsychotics may be minimized by more gradual tapering. There is converging evidence that suggests that adaptations to antipsychotic exposure can persist for months or years after stopping the medication-from animal studies, observation of tardive dyskinesia in patients, and the clustering of relapses in this time period after the cessation of antipsychotics. Furthermore, PET imaging demonstrates a hyperbolic relationship between doses of antipsychotic and D2 receptor blockade. We, therefore, suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): ie, reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance. Some patients may prefer to taper at 10% or less of their most recent dose each month. This process might allow underlying adaptations time to resolve, possibly reducing the risk of relapse on discontinuation. Final doses before complete cessation may need to be as small as 1/40th a therapeutic dose to prevent a large decrease in D2 blockade when stopped. This proposal should be tested in randomized controlled trials.

Overview

CoChat Summary

TL;DR

The paper proposes that antipsychotics should be tapered gradually over months or years and in a hyperbolic manner—reducing by fractions of the most recent dose that correspond to roughly even decrements in D2 receptor blockade—to minimize withdrawal-related relapse. It argues this hypothesis is supported by converging evidence on dopamine supersensitivity, tardive dyskinesia, relapse clustering after cessation, and PET dose-occupancy relationships, but it has not been tested in randomized controlled trials.

Key findings

  • The authors recommend reductions of one quarter or one half of the most recent antipsychotic dose, approximately equivalent to 5 or 10 percentage-point reductions in D2 blockade, at intervals of 3–6 months, titrated to individual tolerance; some patients may prefer reductions of 10% or less of the most recent dose each month.
  • Final doses before complete cessation may need to be as small as 1/40th of a therapeutic dose to avoid a large drop in D2 blockade when stopped.
  • A meta-analysis cited by the authors found relapse rates over the next year of 77% after abrupt stopping, 57% after stopping over 1–2 weeks, 47% after 3–10 weeks, and 31% after tapering longer than 10 weeks.
  • PET data show a hyperbolic dose–D2 occupancy relationship; for haloperidol, linear dose reductions from 4 mg produce increasingly large occupancy drops: 3.5 percentage points from 4 to 3 mg, 6.1 from 3 to 2 mg, 13.7 from 2 to 1 mg, and 55.7 from 1 to 0 mg.

Methods

  • Narrative review and hypothesis paper synthesizing animal studies, human PET imaging, case reports, observational studies, and randomized discontinuation trials; no new primary data are collected.
  • The authors review relapse patterns after antipsychotic discontinuation, evidence on tardive dyskinesia and dopaminergic hypersensitivity, and PET-derived dose–D2 occupancy relationships.
  • They use Emax equations of the form y = maximal occupancy × x/(x + ED50) to derive hyperbolic tapering schedules for six antipsychotics, with doses rounded and intended to be individualized.

Limitations

  • The paper states that PET studies have relatively small sample sizes and may not capture individual variation, though the hyperbolic shape of the dose–activity curve is expected to be universal; heterogeneity in PET meta-analyses suggests interindividual differences in receptor occupancy for a given dose.
  • The paper states that it is difficult to determine whether D2 occupancy linearly corresponds to withdrawal effects, and that other receptor targets such as 5HT2, 5HT1A, and cholinergic receptors may also determine withdrawal effects, particularly for clozapine.
  • The text makes evident that the proposed tapering method is a hypothesis not yet tested in randomized controlled trials; the authors explicitly state that it should be tested in further tapering trials, and the figures’ time frames are described as theoretical, based on few small studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/schbul/sbab017

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Symptoms of the antipsychotic withdrawal syndrome, adapted from Chouinard et al.23
Fig. 1. Symptoms of the antipsychotic withdrawal syndrome, adapted from Chouinard et al.23CC BY-NC · PubMed Central
Fig. 2. The effect of linear or hyperbolic reductions of dose of antipsychotic on D2 receptor occupancy. (A) Relationship between haloperidol dose and D2 dopaminergic receptor occupancy (%) on PET, adapted from the equation for the line of best fit in Lako et al.91 (B) Linear dose reductions of haloperidol produce hyperbolically increasing changes in D2 occupancy, with the largest decrease of 55.7 percentage points of D2 occupancy occurring when the dose is reduced from 1 mg to 0. (C) Hyperbolically decreasing doses of haloperidol correspond to linear reductions in D2 dopaminergic occupancy (in this case, intervals of 20 percentage points of D2 occupancy). The doses in this case correspond to 4.4 mg (80% D2 occupancy), 1.2 mg (60% D2 occupancy), 0.50 mg (40% D2 occupancy), and 0.18 mg (20% D2 occupancy).
Fig. 2. The effect of linear or hyperbolic reductions of dose of antipsychotic on D2 receptor occupancy. (A) Relationship between haloperidol dose and D2 dopaminergic receptor occupancy (%) on PET, adapted from the equation for the line of best fit in Lako et al.91 (B) Linear dose reductions of haloperidol produce hyperbolically increasing changes in D2 occupancy, with the largest decrease of 55.7 percentage points of D2 occupancy occurring when the dose is reduced from 1 mg to 0. (C) Hyperbolically decreasing doses of haloperidol correspond to linear reductions in D2 dopaminergic occupancy (in this case, intervals of 20 percentage points of D2 occupancy). The doses in this case correspond to 4.4 mg (80% D2 occupancy), 1.2 mg (60% D2 occupancy), 0.50 mg (40% D2 occupancy), and 0.18 mg (20% D2 occupancy).CC BY-NC · PubMed Central
Fig. 3 Theoretical representation of abrupt vs gradual reduction of antipsychotic dose. (A) Untreated schizophrenia is represented by postsynaptic D2 receptors (open circles). Antipsychotics cause blockade of D2 receptors (filled in circles). Chronic treatment is hypothesized to cause the upregulation of D2 receptors. (B) Abrupt cessation of antipsychotic causes a large increase in dopaminergic transmission in sensitized D2 receptors, possibly associated with an increased risk of relapse. (C) (i) Gradual reduction in antipsychotic dose leads to incrementally increased dopaminergic transmission, possibly associated with a smaller increase in the risk of relapse or temporary increase in symptoms. Over time (likely months or years) D2 upregulation starts to resolve. (ii)–(iv) Gradual antipsychotic dose reduction is repeated. Please note the time frames indicated here are theoretical, based on few small studies.95,100
Fig. 3 Theoretical representation of abrupt vs gradual reduction of antipsychotic dose. (A) Untreated schizophrenia is represented by postsynaptic D2 receptors (open circles). Antipsychotics cause blockade of D2 receptors (filled in circles). Chronic treatment is hypothesized to cause the upregulation of D2 receptors. (B) Abrupt cessation of antipsychotic causes a large increase in dopaminergic transmission in sensitized D2 receptors, possibly associated with an increased risk of relapse. (C) (i) Gradual reduction in antipsychotic dose leads to incrementally increased dopaminergic transmission, possibly associated with a smaller increase in the risk of relapse or temporary increase in symptoms. Over time (likely months or years) D2 upregulation starts to resolve. (ii)–(iv) Gradual antipsychotic dose reduction is repeated. Please note the time frames indicated here are theoretical, based on few small studies.95,100CC BY-NC · PubMed Central

Verification

Claims the paper makes

14 Valid · 3 Not valid · 35 Not checked · 19 Own results and interpretations

41 more claims · 6 with their cited sources checked

Create a free account to see all 71 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 127 references

Research works printed but not linked: 4

  1. McGorry, 2013, Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more, JAMA Psychiatry., 70, 898, 10.1001/jamapsychiatry.2013.264 · DOI
  2. Seeman, 2014, Yes, Breast is best but taper domperidone when stopping (e-letter), Br J Gen Pract.
  3. American Psychiatric Association, 2020, Guideline statements and implementation., 312
  4. Lehman, 2004, Practice guideline for the treatment of partients with schizophrenia, Am J Psychiatry, 161, 1

Cited by

See all 157

Metadata

Authors
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D.
Affiliations
  • Goodmayes Hospital (GB)
  • King's College London (GB)
Corresponding author
Horowitz, Mark Abie
Venue
Schizophrenia Bulletin
Published
2021-03-23
Volume
47
Issue
4
Pages
1116-1129
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
OpenAlex
W3137682600
Cited by
157
References
127
Citations by year
2026: 28 · 2025: 33 · 2024: 24 · 2023: 32 · 2022: 24 · 2021: 15
FWCI
17.03
Type
journal article
Language
en
Open access
Locations
  • Schizophrenia Bulletin (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
Funders
  • North East London NHS Foundation Trust
  • Royal College of Physicians of Edinburgh
  • National Institute for Health Research Biomedical Research Centre
  • South London and Maudsley NHS Foundation Trust
  • King’s College London
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
antipsychotic tapering, antipsychotic discontinuation
MeSH terms
Drug Administration Schedule, Female, Humans, Male, Recurrence, Schizophrenia, Antipsychotic Agents, Risk Assessment, Withholding Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. https://app.cochat.ai/papers/10.1093/schbul/sbab017
The paper
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbab017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.